Sydney, 1 March 2022. VIATRIS has entered into a five-year agreement with TerryWhite Chemmart and Symbion pharmacy brands, Pharmacy Choice and healthSAVE.
The agreement will help to provide a secure supply of high-quality generic medicines to stores nationally.
“We’re pleased to further strengthen our partnership with EBOS Group to now also include TerryWhite Chemmart, and Symbion pharmacy brands, Pharmacy Choice and healthSAVE. All of these community pharmacies share our mission of providing access to high quality and affordable medicines so Australians can live healthier lives”, said Sylvain Vigneault, Viatris Country Manager, Australia.
“Through our local manufacturing and distribution facilities in Queensland, Viatris is well positioned to bring medicines to Australians when and where they need them.”
TerryWhite Chemmart welcomed 43 new pharmacies to their network last year and with over 480 stores, they are Australia’s largest health-advice orientated community pharmacy network (1). Pharmacy Choice currently has more than 700 members Australia wide and healthSAVE has over 75 stores nationally.
The agreements with Pharmacy Choice and healthSAVE pharmacy brands commence on 1 April 2022 and the agreement with the TerryWhite Chemmart pharmacy brand commences on 2 July 2022.(1) EBOS Group Interim Shareholders Report 2022
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 38,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
Communications Manager, Australia and New Zealand
M: +61 449 902 687